Lilburn, GA, United States of America

Xiangxue Gao


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Xiangxue Gao in Targeted Cancer Treatment

Introduction

Xiangxue Gao is an accomplished inventor based in Lilburn, GA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patent developments. His work focuses on targeted protease compositions that have the potential to revolutionize cancer therapies.

Latest Patents

Xiangxue Gao holds a patent for "Targeted protease compositions and uses related thereto." This patent describes targeted protease compositions that utilize nanoparticles linked to a targeting molecule and a catalytic domain of a protease. The targeting molecule is designed to bind to molecules that are more highly expressed on cancer cells compared to non-cancerous cells. This innovative approach allows for the treatment of cancer by attaching an anti-cancer agent to the nanoparticle or incorporating it within the nanoparticle.

Career Highlights

Xiangxue Gao is affiliated with Emory University, where he conducts research and develops his innovative ideas. His work has garnered attention for its potential applications in cancer treatment, showcasing his commitment to advancing medical science.

Collaborations

Xiangxue Gao collaborates with fellow researcher Lily Yang, contributing to the development of targeted therapies and enhancing the effectiveness of cancer treatments.

Conclusion

Xiangxue Gao's innovative work in targeted protease compositions represents a significant advancement in cancer treatment. His contributions to the field highlight the importance of research and innovation in developing effective therapies for challenging medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…